Fig. 8 | Signal Transduction and Targeted Therapy

Fig. 8

From: m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance

Fig. 8

HNF3γ levels in patient HCCs correlate with sorafenib benefit. a The correlation between HNF3γ expression and AFP levels was evaluated in 67 HCC patients using a chi-square test. b The correlation between HNF3γ expression and HCC differentiation was evaluated in patient HCC tissues using a chi-square test (left). H&E and IHC staining for the dedifferentiation markers AFP and CK19 were conducted, and the representative images are shown (right). Scale bar, 100 μm. c HNF3γ expression was examined by IHC staining in HCC samples from 96 patients who had received adjuvant sorafenib therapy after surgery. Overall survival of patients between the HNF3γ-high and HNF3γ-low groups was compared with Kaplan–Meier analysis. d HNF3γ expression was examined by IHC staining in primary HCC samples from 85 patients who had received sorafenib treatment for recurrent tumors. The overall survival of patients between the HNF3γ-high and HNF3γ-low groups was analyzed with Kaplan–Meier analysis. e, f PDXs with high or low HNF3γ expression in their primary HCC tumors indicated by IHC staining scores (details can be found in “Materials and methods”) were treated with sorafenib (30 mg/kg body weight) or vehicle for 28 days. Xenografted tumor growth was monitored, and the tumor growth rates were calculated

Back to article page